Melissa Cadnapaphornchai, MD
Professor of Clinical Pediatrics (Nephrology)
Department: Pediatrics
Contact information
Children's Hospital of Philadelphia
3500 Civic Center Blvd.
Philadelphia, PA 19104
3500 Civic Center Blvd.
Philadelphia, PA 19104
Education:
B.S. (Biomedical Sciences, Integrated Flexible Premedical/Medical Program)
University of Michigan, Ann Arbor, 1990.
M.D.
University of Michigan Medical School, 1993.
Permanent linkB.S. (Biomedical Sciences, Integrated Flexible Premedical/Medical Program)
University of Michigan, Ann Arbor, 1990.
M.D.
University of Michigan Medical School, 1993.
Selected Publications
Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Goldstein SL, Dandurand A, Jiang H, Jadhav P, Debuque L.: Estimating risk of rapid disease progression in pediatric patients with autosomal dominant polycystic kidney disease: a randomized trial of tolvaptan. Pediatr Nephrol 2024.Gitomer BY, Wang W, George D, Coleman E, Nowak KL, Struemph T, Cadnapaphornchai MA, Patel NU, Jovanovich A, Klawitter J, Farmer B, Ostrow A, You Z, Chonchol M.: Statin therapy in patients with early-stage autosomal dominant polycystic kidney disease: Design and baseline characteristics. Contemp Clin Trials 2024.
Michelle N Rheault, Charles E Alpers, Jonathan Barratt, Stewart Bieler, Pietro Canetta, Dong-Wan Chae, Gaia Coppock, Ulysses Diva, Loreto Gesualdo, Hiddo J L Heerspink, Jula K Inrig, Gianna M Kirsztajn, Donald Kohan, Radko Komers, Laura A Kooienga, Kenneth Lieberman, Alex Mercer, Irene L Noronha, Vlado Perkovic, Jai Radhakrishnan, William Rote, Brad Rovin, Vladimir Tesar, Hernán Trimarchi, James Tumlin, Muh Geot Wong, Howard Trachtman; DUPRO Steering Committee and DUPLEX Investigators: Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. N Engl J Med 389(26): 2436-2445, Dec 2023.
Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Zhang Z, Sikes K, Shoaf SE, Schaefer F: Phase 3 trial of tolvaptan in pediatric autosomal dominant polycystic kidney disease (ADPKD): Two years of data from an open-label extension. Poster presentation, European Society for Pediatric Nephrology 55th Annual Meeting, Vilnius, Lithuania Sep 2023.
Yang X, Wang W, Gitomer B, Cadnapaphornchai MA, Xing F, Chonchol M: Imaging biomarkers in young patients with ADPKD. Kidney Int Rep 8(10): 2153-2155, Jul 2023.
Mekahli D, Guay-Woodford LM, Cadnapaphornchai MA, Greenbaum LA, Litwin M, Seeman T, Dandurand A, Zhang Z, Sikes K, Shoaf SE, Schaefer F: Phase 3 trial of tolvaptan in pediatric autosomal dominant polycystic kidney disease (ADPKD): Two years of data from an open-label extension. Poster presentation, European Renal Assocation 60th Congress, Milan, Italy Jun 2023.
Mekahli D, Liebau MC, Cadnapaphornchai MA, Goldstein SL, Greenbaum LA, Litwin M, Seeman T, Schaefer F, Guay-Woodford LM: Design of two ongoing clinical trials of tolvaptan in the treatment of pediatric patients with autosomal recessive polycystic kidney disease. BMC Nephrol 24(1): 33, Feb 2023.
Mekahli D, Guay-Woodford L, Cadnapaphornchai MA, Greenbaum L, Mieczyslaw L, Seeman T, Dandurand A, Shi L, Sikes K, Shoaf S, Schaefer F: Tolvaptan for children and adolescents with autosomal dominant polycystic kidney disease: Randomized controlled trial. Clin J Am Soc Nephrol 18(1): 36-46, Jan 2023.
Klawitter J, Jackson MJ, Smith PH, Hopp K, Chonchol M, Gitomer BY, Cadnapaphornchai MA, Christians U, Klawitter J : Kynurenines in polycystic kidney disease. J Nephrol 2023 36(1): 83-91, Jan 2023.
Cadnapaphornchai MA, Ong ACM: Hypertension in young adults with autosomal dominant polycystic kidney disease: a case for early screening? Clin Kidney J 16(6): 901-904, Jan 2023.